Prostatype Genomics AB (PROGEN) — Cash Flow Reinvestment Rate
Latest as of June 2020:
0.06x
Prostatype Genomics AB (PROGEN) has a Cash Flow Reinvestment Rate of 0.06x as of June 2020, reinvesting Skr361.71K (capex Skr361.71K ) from operating cash flow of Skr5.63 Million. Explore capital reinvestment ratio of Prostatype Genomics AB to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
0.06x
(Capex + Investments) / Operating CF
Total Reinvested
Skr361.71K
Capex + Investments
Operating Cash Flow
Skr5.63 Million
SEK
Capital Expenditures
Skr361.71K
SEK
Annual Cash Flow Reinvestment Rate for Prostatype Genomics AB (None–None)
Year-by-year capital reinvestment analysis for Prostatype Genomics AB. For live market cap and broader valuation context, see Prostatype Genomics AB market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow